Bio-Techne Announces Launch Of ExoCovid-19 Test For Detection Of SARS-CoV-2 In Patient Samples

Rhea-AI Summary

Bio-Techne Corporation (NASDAQ:TECH) announced the launch of the ExoCovid-19 test, which has been validated for detecting COVID-19 caused by SARS-CoV-2. This test is conducted in a CLIA-certified, CAP-accredited laboratory and allows for minimally invasive nasal swab specimen collection. The assay has received Emergency Use Authorization (EUA) from the FDA and is designed to enhance testing capabilities during the pandemic. The company aims to expand its COVID-19 testing offerings to improve accessibility and reliability for patients and healthcare providers.

Positive

• Launch of ExoCovid-19 test with Emergency Use Authorization from FDA.
• Minimally invasive specimen collection method enhances testing accessibility.
• Expansion of high-complexity laboratory capabilities to support COVID-19 testing.

Negative

• None.

MINNEAPOLIS, July 21, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has completed validation testing for COVID-19 caused by the novel coronavirus (SARS-CoV-2) and now offers the ExoCovid-19 test for detection of the virus in patient samples. The ExoCovid-19 test will be performed in its CLIA-certified, CAP-accredited laboratory.

Exosome Diagnostics, the world leader in developing exosomal liquid biopsy-based diagnostic assays, has expanded its high-complexity laboratory capabilities to perform qualitative multiplexing nucleic acid analysis for the sensitive detection and identification of SARS-CoV-2 virus in nasal, nasopharyngeal, and bronchoalveolar lavage patient specimens. 

Exosome Diagnostics has validated the CDC-approved assay which has been granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration for detection of SARS-CoV-2. Unlike many of the earlier tests currently available on the market, the ExoCovid-19 collection kit offers a minimally invasive nasal swab (anterior nares) which enables patients to comfortably self-collect a specimen while maintaining physical distancing from a healthcare provider.

"We continue to closely monitor the ongoing response to COVID-19 and are actively scaling our COVID-19 test offerings for multiple specimen types to increase the availability of high-quality, reliable, and easily-administered laboratory testing," said Johan Skog, Chief Scientific Officer at Exosome Diagnostics.

"Bio-Techne continues to leverage its deep scientific and research expertise to help patients and healthcare providers fight the COVID-19 crisis. This EUA assay is an important addition to our growing portfolio products and services enabling solutions for this evolving pandemic," said Chuck Kummeth, President and Chief Executive Officer of Bio-Techne.

For more information on how to order tests, please visit www.exosomedx.com/covid-19.

About Bio-Techne Corporation (NASDAQ:TECH)

Contact: David Clair, Senior Director, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/bio-techne-announces-launch-of-exocovid-19-test-for-detection-of-sars-cov-2-in-patient-samples-301096642.html

SOURCE Bio-Techne Corporation

FAQ

What is the ExoCovid-19 test from Bio-Techne Corporation?

The ExoCovid-19 test is a diagnostic assay developed by Bio-Techne to detect COVID-19 caused by the SARS-CoV-2 virus using minimally invasive nasal swab specimens.

When did Bio-Techne announce the ExoCovid-19 test?

Bio-Techne announced the launch of the ExoCovid-19 test on July 21, 2020.

Is the ExoCovid-19 test authorized by the FDA?

Yes, the ExoCovid-19 test has received Emergency Use Authorization from the U.S. Food and Drug Administration.

How is the ExoCovid-19 test performed?

The ExoCovid-19 test is performed in a CLIA-certified, CAP-accredited laboratory and involves a minimally invasive nasal swab for specimen collection.

What laboratory capabilities has Bio-Techne expanded for COVID-19 testing?

Bio-Techne has expanded its high-complexity laboratory capabilities for qualitative multiplexing nucleic acid analysis to improve COVID-19 testing.